Simulations Plus, Inc. (SLP)

22.44
NASDAQ
Prev Close 22.44
Day Low/High 0.00 / 0.00
52 Wk Low/High 16.26 / 23.95
Exchange NASDAQ
Shares Outstanding 17.52B
Market Cap 393.04M
Div & Yield N.A. (N.A)

Latest News

Simulations Plus Reports Record Second Quarter FY2019 Revenue

Simulations Plus Reports Record Second Quarter FY2019 Revenue

Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its second quarter of fiscal year 2019,...

SLP Crosses Below Key Moving Average Level

SLP Crosses Below Key Moving Average Level

In trading on Thursday, shares of Simulations Plus Inc. crossed below their 200 day moving average of $19.90, changing hands as low as $19.87 per share.

Simulations Plus Sets Date For 2nd Quarter 2019 Earnings Release And Conference Call

Simulations Plus Sets Date For 2nd Quarter 2019 Earnings Release And Conference Call

Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2019 fiscal year, the period ended February 28, 2019, on Tuesday, April 9, 2019.

Ex-Div Reminder For Simulations Plus (SLP)

Ex-Div Reminder For Simulations Plus (SLP)

Looking at the universe of stocks we cover at Dividend Channel, on 1/24/19, Simulations Plus Inc. will trade ex-dividend, for its quarterly dividend of $0.06, payable on 2/1/19.

DILIsym Awarded $1.5 Million Phase II NIH Grant

DILIsym Awarded $1.5 Million Phase II NIH Grant

DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) developing  in silico modeling software, resources, and information for assisting the pharmaceutical industry to more efficiently develop safe and effective drug therapies, today announced...

Simulations Plus Releases DDDPlus™ Version 6

Simulations Plus Releases DDDPlus™ Version 6

Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 6 of its in vitro dissolution modeling software,...

DILIsym Services Inc. Initiates Development Of IPFsym™

DILIsym Services Inc. Initiates Development Of IPFsym™

DILIsym Services Inc., a Simulations Plus company (Nasdaq:SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it is initiating development of IPFsym™, QSP (quantitative systems...

Notable Two Hundred Day Moving Average Cross - SLP

Notable Two Hundred Day Moving Average Cross - SLP

In trading on Thursday, shares of Simulations Plus Inc. crossed below their 200 day moving average of $19.31, changing hands as low as $18.41 per share.

Simulations Plus To Present At The 21st Annual Needham Growth Conference

Simulations Plus To Present At The 21st Annual Needham Growth Conference

Simulations Plus, Inc. (Nasdaq:SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O'Connor will present at the 21 st...

Simulations Plus Reports First Quarter FY2019 Financial Results

Simulations Plus Reports First Quarter FY2019 Financial Results

Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its first quarter of fiscal year 2019, the...

DILIsym Services Inc. Releases DILIsym® Version 8A

DILIsym Services Inc. Releases DILIsym® Version 8A

DILIsym Services Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it has released DILIsym® Version 8A, its flagship QST (quantitative...

Simulations Plus To Report First Quarter Fiscal Year 2019 Financial Results

Simulations Plus To Report First Quarter Fiscal Year 2019 Financial Results

Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its first quarter financial results for fiscal year 2019, the period ended November 30, 2018, after the close of the financial markets on Wednesday, January 9, 2019.

SLP Crosses Below Key Moving Average Level

SLP Crosses Below Key Moving Average Level

In trading on Thursday, shares of Simulations Plus Inc. crossed below their 200 day moving average of $19.04, changing hands as low as $18.42 per share.

Simulations Plus To Present At LD Micro 11th Annual Main Event Investor Conference On December 4, 2018

Simulations Plus To Present At LD Micro 11th Annual Main Event Investor Conference On December 4, 2018

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software for pharmaceutical discovery and development, today announced that Shawn O'Connor, chief executive officer, and John Kneisel, chief financial officer, will present at the 11th Annual LD...

Simulations Plus Reports FY2018 And Fourth Quarter FY2018 Financial Results

Simulations Plus Reports FY2018 And Fourth Quarter FY2018 Financial Results

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software for pharmaceutical discovery and development, today reported its financial results for its 2018 fiscal year (FY18) and fourth quarter (4Q18) ended August 31, 2018.

Simulations Plus To Report 4th Quarter And Fiscal Year 2018 Financial Results

Simulations Plus To Report 4th Quarter And Fiscal Year 2018 Financial Results

Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2018, ended August 31, 2018, after the close of the financial markets on Wednesday, November 14, 2018.

DILIsym Services, An SLP Company, Launches Consortium For Drug-Related Kidney Injury

DILIsym Services, An SLP Company, Launches Consortium For Drug-Related Kidney Injury

DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of simulation and modeling software for pharmaceutical safety, today announced that it will initiate a quantitative systems toxicology (QST) consortium aimed at...

Simulations Plus About To Put More Money In Your Pocket (SLP)

Simulations Plus About To Put More Money In Your Pocket (SLP)

Looking at the universe of stocks we cover at Dividend Channel, on 10/31/18, Simulations Plus Inc. will trade ex-dividend, for its quarterly dividend of $0.06, payable on 11/8/18.

Simulations Plus Announces Quarterly Cash Dividend Of $0.06 Per Share

Simulations Plus Announces Quarterly Cash Dividend Of $0.06 Per Share

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that its board of directors has declared its next ongoing...

Simulations Plus Receives New Grant Award From The FDA

Simulations Plus Receives New Grant Award From The FDA

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received notice from the U.

Simulations Plus Extends Funded Research Collaboration With The FDA

Simulations Plus Extends Funded Research Collaboration With The FDA

Simulations Plus, Inc. (Nasdaq:SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a one-year funded extension to its...

Reminder - Simulations Plus (SLP) Goes Ex-Dividend Soon

Reminder - Simulations Plus (SLP) Goes Ex-Dividend Soon

Looking at the universe of stocks we cover at Dividend Channel, on 7/25/18, Simulations Plus Inc. will trade ex-dividend, for its quarterly dividend of $0.06, payable on 8/2/18.

Simulations Plus Subsidiary DILIsym Awarded Grant For Up To $1.7 Million For Model Development

Simulations Plus Subsidiary DILIsym Awarded Grant For Up To $1.7 Million For Model Development

DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) developing in silico modeling software, resources, and information for assisting the pharmaceutical industry to more efficiently develop safe and effective drug therapies, today announced it...

Simulations Plus Enters Funded Research Collaboration With Large European Consortium

Simulations Plus Enters Funded Research Collaboration With Large European Consortium

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a one-year funded research...

SLP Makes Notable Cross Below Critical Moving Average

SLP Makes Notable Cross Below Critical Moving Average

In trading on Thursday, shares of Simulations Plus Inc. crossed below their 200 day moving average of $17.24, changing hands as low as $16.70 per share.

Simulations Plus Reports Third Quarter FY2018 Financial Results

Simulations Plus Reports Third Quarter FY2018 Financial Results

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its third quarter of fiscal year 2018...

Notable Tuesday Option Activity: SLP, OFG, ITCI

Notable Tuesday Option Activity: SLP, OFG, ITCI

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Simulations Plus Inc. , where a total volume of 1,221 contracts has been traded thus far today, a contract volume which is representative of approximately 122,100 underlying shares (given that every 1 contract represents 100 underlying shares).

Simulations Plus To Report Third Quarter 2018 Financial Results

Simulations Plus To Report Third Quarter 2018 Financial Results

Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its third quarter financial results for fiscal year 2018, the period ended May 31, 2018, after the close of the financial markets on Tuesday, July 10, 2018.

TheStreet Quant Rating: B (Buy)